

BIO BLAST PHARMA LTD.  
Form SC 13G  
February 17, 2015

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**(Rule 13d-102)**

**Under the Securities Exchange Act of 1934  
(Amendment No. )\***

**Bio Blast Pharma Ltd.**

(Name of Issuer)

**Ordinary Shares**

(Title of Class of Securities)

**M20156101**

(CUSIP Number)

**December 31, 2014**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. M20156101 13G Page 2 of 6 Pages

Names of Reporting Persons

1.

**Dr. Dalia Megiddo**  
CHECK THE APPROPRIATE  
BOX IF A MEMBER OF A  
GROUP\*

(See Instructions)

2.

(a) "

(b) "

SEC Use Only

3.

Citizenship or Place of  
Organization

4.

**Israel**  
Sole Voting Power

NUMBER OF 5.

SHARES 3,311,421  
Shared Voting Power

BENEFICIALLY

OWNED BY 6.

EACH 0  
Sole Dispositive Power

REPORTING 7.

PERSON 3,311,421

**WITH**

**8.** Shared Dispositive Power

**0**

Aggregate Amount Beneficially  
Owned by Each Reporting  
Person

**9.**

**3,311,421**

Check if the Aggregate Amount  
in Row (9) Excludes Certain  
Shares "

**10.**

(See Instructions)

Percent of Class Represented by  
Amount in Row (9)

**11.**

**23.3%**

Type of Reporting Person (See  
Instructions)

**12.**

**IN**

**CUSIP No. M20156101 13G Page 3 of 6 Pages**

**Item 1(a). Name of Issuer:**

Bio Blast Pharma Ltd.

**Item 1(b). Address of Issuer's Principal Executive Offices:**

37 Dereh Menachem Begin St., 15<sup>th</sup> Floor

Tel Aviv 6522042 Israel

**Item 2(a). Name of Person Filing:**

This Statement is filed on behalf of Dalia Megiddo (the "Reporting Person").

**Item 2(b). Address of Principal Offices or, if None, Residence:**

The address of the Reporting Person is:

37 Dereh Menachem Begin St., 15<sup>th</sup> Floor

Tel Aviv 6522042 Israel

**Item 2(c). Citizenship:**

Dalia Megiddo is an Israeli citizen.

**Item 2(d). Title of Class of Securities:**

Ordinary Shares

**Item 2(e). CUSIP Number:**

M20156101

**Item 3. If the Statement is being filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the filing person is a:**

Not applicable.

- (a) " Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) " Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) " Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) " Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) " An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) " An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) " A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) " A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) " A church plan that is excluded from the definition of an investment company under Section K(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
- (j) " A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
- (k) " Group, in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: \_\_\_\_\_

**CUSIP No. M20156101 13G Page 4 of 6 Pages**

**Item 4. Ownership.**

(a) Amount beneficially owned:

3,311,421 shares

(b) Percent of class:

23.3%

(c) Number of shares as to which such person has:

(i) Sole power to vote or direct the vote: 3,311,421 shares

(ii) Shared power to vote or direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 3,311,421 shares

(iv) Shared power to dispose or to direct the disposition of: 0

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person had ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following " .

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

Not applicable.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable.

**Item 9. Notice of Dissolution of Group.**

Not applicable.

**CUSIP No. M20156101 13G Page 5 of 6 Pages**

**Item 10. Certification.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**CUSIP No. M20156101 13G Page 6 of 6 Pages**

**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 15, 2015  
(Date)

/s/ Dr. Dalia Megiddo  
(Signature)

*Attention.* Intentional misstatements or omissions of fact constitute Federal criminal violations (*see* 18 U.S.C. 1001).